



Published in final edited form as:

Alzheimers Dement. 2019 March ; 15(3): 418–428. doi:10.1016/j.jalz.2018.09.008.

Hypertension and obesity moderate the relationship between beta-amyloid and cognitive decline in midlife

Lindsay R. Clark, PhD^{a,b,c}, Rebecca L. Kosciak, PhD^b, Samantha L. Allison, PhD^a, Sara E. Berman, PhD^{a,d}, Derek Norton, MS^{a,e}, Cynthia M. Carlsson, MD^{a,b,c}, Tobey Betthausen, PhD^{a,f}, Barbara B. Bendlin, PhD^a, Bradley T. Christian, PhD^{a,f}, Nathaniel Chin, MD^a, Sanjay Asthana, MD^{a,c}, and Sterling C. Johnson, PhD^{a,b,c}

^aAlzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.

^bWisconsin Alzheimer's Institute, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.

^cGeriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, WI 53705, USA.

^dMedical Scientist and Neuroscience Training Programs, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.

^eDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI 53792, USA.

^fWaisman Center and Department of Medical Physics, University of Wisconsin, Madison, WI 53792, USA.

Abstract

BACKGROUND: This study tested if central obesity, hypertension, or depressive symptoms moderated the relationship between beta-amyloid ($A\beta$) and longitudinal cognitive performance in late middle-aged adults enriched for Alzheimer's disease (AD) risk.

METHODS: Participants ($n=207$; ages=40–70; 73% parental AD) in the Wisconsin Registry for Alzheimer's Prevention study completed 3+ neuropsychological evaluations and a [^{11}C]PiB PET scan or lumbar puncture. Linear mixed-effects regression models tested interactions of risk factor $\times A\beta \times$ visit age on longitudinal Verbal Learning & Memory (VLM) and Speed & Flexibility (SF) factor scores.

Corresponding author: Lindsay R. Clark, PhD, University of Wisconsin Madison School of Medicine & Public Health, 600 Highland Avenue, J5/1 Mezzanine, Madison, WI, 53792, USA. Phone: 608-263-4405; Fax: 608-265-3091; lrclark@medicine.wisc.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

RESULTS: The relationship between A β and VLM decline was moderated by hypertension ($\chi^2(1) = 3.85, p = .04$) and obesity ($\chi^2(1) = 6.12, p = .01$); those with both elevated A β and the risk factor declined at faster rates than those with only elevated A β or elevated risk factors.

CONCLUSION: In this cohort, hypertension and obesity moderated the relationship between A β and cognitive decline.

Keywords

preclinical Alzheimer's disease; beta-amyloid; hypertension; obesity; depression; neuropsychology

1. INTRODUCTION

Although available treatments for Alzheimer's disease (AD) may provide some short-term benefits, they have limited efficacy in terms of modifying the course of the disease [1, 2]. The lack of an effective disease-modifying therapy has led to increased efforts targeted at both early detection of AD and modifiable risk factors that may influence disease progression. Two commonly used ante-mortem biomarkers allowing for early detection of AD-related pathology are [^{11}C]PiB positron emission tomography (PET), which allows for imaging of beta-amyloid (A β) plaques in vivo [3], and cerebrospinal fluid (CSF) levels of A β 1–42 (A β_{42}), which are correlated with the formation of A β plaques in the brain [4, 5]. Prior investigations indicate that cognitively unimpaired adults with higher mean cortical [^{11}C]PiB binding potential and/or lower CSF A β_{42} are at increased risk of developing dementia [6–9]. Furthermore, cognitively healthy adults with elevated A β deposition are more likely to exhibit cognitive decline than adults with lower A β levels [10–14]; however, up to 30% of older adults with elevated A β remain cognitively unimpaired in late life [15]. This finding suggests that not all adults with elevated A β accumulation will progress to dementia, and that other factors may moderate the relationship between A β and cognitive decline.

Supporting this hypothesis, epidemiological studies suggest that seven potentially modifiable risk factors for AD, including midlife hypertension, midlife obesity, smoking, depression, low educational attainment, physical inactivity, and diabetes may account for up to half of dementia cases in the United States [16]. Several studies report greater risk for dementia and/or longitudinal decline on neuropsychological measures in adults with depressive symptomatology [17–24], obesity [24–30], or hypertension [28, 31–35]. Moreover, prior investigations revealed elevated A β deposition in non-demented older adults with depression [36] or hypertension [37–38]. Two recent studies also observed a relationship between midlife obesity and increased A β in later life [39, 40]. Finally, one prior investigation demonstrated that adults with abnormal plasma A β levels and elevated blood pressure at midlife were at greatest risk of developing AD [41]; however, no study to date has examined if the relationships between these modifiable risk factors and A β deposition interact to affect longitudinal cognitive performance in cognitively unimpaired adults.

Therefore, the purpose of the current study was to determine if the presence of modifiable risk factors moderates the relationship between A β level and longitudinal performance on neuropsychological measures in cognitively normal late middle-aged adults. This study focuses on three midlife modifiable risk factors that were well-characterized in the Wisconsin Registry for Alzheimer's Prevention (WRAP) cohort: hypertension, obesity, and depression. We investigated the moderating effects of these risk factors on the relationship between A β deposition (as assessed via [^{11}C]PiB PET imaging or CSF A β_{42}) and longitudinal neuropsychological performance. We hypothesized that each risk factor would moderate the relationship between A β burden and longitudinal cognitive performance (i.e., three-way interaction among visit age (time-varying) x risk factor group (time-invariant) x A β group (time-invariant)) would account for a significant amount of variance in longitudinal neuropsychological performance.

2. MATERIALS AND METHODS

2.1 Participants

Data were from 207 participants enrolled in the WRAP study, which consists of a cohort of ~1550 asymptomatic (at study entry) late middle-aged adults enriched for parental history of AD [42]. The ongoing parent study includes biennial evaluations (with the exception of a four-year interval between visits 1 and 2) that involve a physical exam, labs, a neuropsychological evaluation, and optional linked studies for acquisition of neuroimaging and CSF biomarkers of AD pathophysiology. Inclusion criteria for this study were as follows: cognitive data for at least three longitudinal visits, no diagnosis of dementia as determined via consensus conference review using NIA-AA diagnostic criteria [43], and completion of either a [^{11}C]PiB PET scan or lumbar puncture. The inclusion of human subjects in this study was approved by the University of Wisconsin-Madison Institutional Review Board and all participants provided informed consent.

2.2 Beta-amyloid status determination

The biomarker data were collected as part of linked study protocols and did not occur at the same study visit for all participants (see Figure 1). Biomarker data were collected at visit 2 for $n=61$ participants, at visit 3 for $n=111$ participants, and at visit 4 for $n=35$ participants. Elevated or non-elevated A β status was determined by mean [^{11}C]PiB distribution volume ratio (DVR) or by CSF A β_{42} or A $\beta_{42}/\text{A}\beta_{40}$ levels.

Detailed methods for [^{11}C]PiB radiochemical synthesis, PET imaging parameters, and parametric DVR map generation were implemented as described previously [44]. Eight bilateral regions of interest (angular gyrus, anterior cingulate gyrus, posterior cingulate gyrus, frontal medial orbital gyrus, precuneus, supramarginal gyrus, middle temporal gyrus, and superior temporal gyrus) were selected from the automated anatomic labeling atlas, standardized, and reverse warped to native space. The mean DVR across these eight regions of interest was calculated for determination of A β status (elevated or non-elevated) using a cutoff of 1.19 as previously reported for the WRAP cohort [45].

CSF was collected in the morning after a minimum 12-hour fast. A Sprotte spinal needle was used to extract 22 mL of CSF from the L3-L4 or L4-L5 vertebral interspace via gentle extraction into polypropylene syringes. Within 30 minutes of collection, the CSF was combined, gently mixed, centrifuged to remove red blood cells or other debris, aliquoted into 0.5-mL polypropylene tubes, and stored at -80°C . Samples were analyzed at the Clinical Neurochemistry Laboratory at the Sahlgrenska Academy of the University of Gothenburg, Sweden for $\text{A}\beta_{1-40}$ and $\text{A}\beta_{1-42}$ using commercially available enzyme-linked immunosorbent assay methods (INNOTEST assays, Fujirebio, Ghent, Belgium; Triplex assays, MSD Human $\text{A}\beta$ peptide ultra-sensitive kit, Meso Scale Discovery, Gaithersburg, MD). An $\text{A}\beta_{42}$ (innotest) value < 471.54 pg/ml or an $\text{A}\beta_{42}/\text{A}\beta_{40}$ (triplex) ratio $< .09$ was used to define elevated $\text{A}\beta$, based on prior receiver operating characteristic analyses showing these values best discriminated cognitively healthy adults from individuals with dementia[46].

2.3 Modifiable Risk Factor Assessment

The modifiable risk factors included in this study were hypertension, obesity, and depression, which were chosen because they were midlife modifiable risk factors included in the epidemiological study previously described [16] and were present in $>10\%$ of the entire WRAP cohort (diabetes was present in only 5% of the cohort and current tobacco use was present in only 9% of the cohort). The data included in this study were collected at the closest point in time to the biomarker visit (mean time between risk factor data and biomarker data = 0.65 years, range = 0–2 years). Blood pressure and anthropometric measures were obtained according to the Atherosclerosis Risk in Communities Study protocol. Prior to cognitive test administration, participants were instructed to sit for 10 minutes and then have blood pressure readings obtained. Blood pressure was measured up to three times within an examination visit to obtain a stable measure, with the participant seated using a random-zero sphygmomanometer. Cuff size was chosen appropriate to the participant's arm circumference. Hypertension was defined according to the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure 8 guidelines [47] (i.e., systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg). Use of antihypertensive medication was included as a covariate in primary analyses and examined further in post-hoc analyses. Waist circumference was measured with an anthropometric tape to the nearest centimeter with the participant standing. The waist circumference was taken at the level of the natural waist (narrowest part). Waist measurements were taken twice by trained staff and the smallest measurement was used. Waist circumference measurements greater than 88 cm for women and 102 cm for men were coded as obese based on standard guidelines [48]. Depressive symptoms were assessed using the Center for Epidemiologic Studies of Depression scale (CES-D), with total scores ≥ 16 coded as depressed [49]. Risk factor variables were dichotomized using clinically-defined cut-points to improve interpretability, generalizability, and clinical relevance.

2.4 Cognitive Assessment

A comprehensive neuropsychological assessment was completed at each visit [42]. A prior factor analysis indicated that learning trials 3–5 and the delayed recall trial (trial 7) on the Rey Auditory Verbal Learning Test loaded onto a Verbal Learning & Memory factor and that

measures of speed and executive function (Trailmaking Test Parts A & B, Stroop Color-Word Interference condition) loaded onto a Speed & Flexibility factor [50]. Each factor was calculated as a weighted composite of the contributing tests and then standardized around the baseline mean and standard deviation of the composite (i.e., each factor is a z-score) [51]. These factors were selected for analyses because they represent cognitive domains that have been shown to exhibit early decline, are associated with A β in preclinical AD based on prior meta-analyses [52–54], and include measures that were given at all study visits.

2.5 Statistical Analysis

To test for the presence of relationships between A β status and modifiable risk factors, chi-square analyses were conducted for the dichotomous risk factor variables and ANOVAs were conducted for the continuous risk factor variables in SPSS version 24. To test the hypothesis that longitudinal cognitive performance would vary by risk factor and A β status, linear mixed-effects regression analysis was conducted in R version 3.3.1 using the lme4 package version 1.1–12 [55]. Linear mixed-effects models were used due to their ability to handle unbalanced and missing data as well as a continuous variable for time [56]. Outcome variables were Verbal Learning & Memory and Speed & Flexibility factor scores. Random effects included intercept and slope nested within-subject. Fixed effects for model 1 included main effects of hypertension status, A β status, and age at each visit (time-varying variable; centered on the sample mean) and interaction terms of hypertension status x A β status, age at each visit x hypertension status, age at each visit x A β status, and age at each visit x hypertension status x A β status. Fixed effects for models 2 and 3 were identical to model 1 except for obesity status and depression status instead of hypertension. Covariates included age at biomarker visit, sex, education, practice effects (time-varying variable; number of prior exposures to cognitive test [total visits completed – 1]), and treatment status (e.g., antihypertensive medication use (yes vs. no) for model 1 or antidepressant medication use (yes vs. no) for model 3). The overall significance of the three-way interaction term was assessed by likelihood ratio tests comparing the full model and a nested model that did not include the three-way interaction term. Statistical comparison of model coefficients to determine direction of group differences was performed using the Wald test. Statistical tests were two-tailed and an alpha-level of $p < .05$ was used to determine statistical significance. Model fit was evaluated by visual inspection of the residuals and a Pearson goodness-of-fit test.

3. RESULTS

3.1 Sample characteristics

The sample was on average 55 years of age at study enrollment and 61 years of age at biomarker visit. The sample was 68% female, highly educated (mean 16 years of education), and enriched for Alzheimer's disease risk (73% had at least one parent with Alzheimer's disease; 38% apolipoprotein (*APOE*) ϵ 4 genotype carriers; see Table 1). All 207 participants completed at least three neuropsychological evaluations. Twenty-five participants (12%) completed three study visits (six years follow-up), 82 (40%) completed four study visits (eight years follow-up), and 100 (48%) completed five study visits (ten years follow-up). There was a mean of 6 months between the neuropsychological evaluation and biomarker

visit (range = 0–2 years) and this did not differ between A β groups ($t(205) = 0.43, p = .67$). Sixty-two participants (30%) exhibited elevated levels of A β . At the study visit closest to the biomarker assessment, $n = 40$ (19%) were hypertensive, $n = 89$ (43%) were obese, and $n = 13$ (6%) were depressed. Results of chi-square analyses indicated no significant association between hypertension and obesity status ($\chi^2(1) = 0.99, p = .32$), hypertension and depression status ($\chi^2(1) = 0.14, p = .71$), or obesity and depression status ($\chi^2(1) = 1.95, p = .16$).

3.2 Relationship between modifiable risk factors and beta-amyloid status

Results of chi-square analyses indicated that risk factor status did not differ by A β status (see Table 2). Specifically, there were no differences in proportion of participants with elevated A β by hypertension status ($\chi^2(1) = .15, p = .70$), obesity status ($\chi^2(1) = 2.04, p = .15$), or depression status ($\chi^2 = .004, p = .95$). Similarly, there were no differences between A β groups in systolic blood pressure ($F = 0.06, p = .80$; estimated marginal means: A β - = 125.6 [95% CI: 123.0–128.2], A β + = 126.2 [95% CI: 122.2–130.1]), diastolic blood pressure ($F = 0.04, p = .84$; estimated marginal means: A β - = 74.4 [95% CI: 72.8–76.0], A β + = 74.7 [95% CI: 72.2–77.1]), waist circumference ($F = 1.62, p = .21$; estimated marginal means: A β - = 93.2 [95% CI: 90.8–95.6], A β + = 90.32 [95% CI: 86.6–94.1]), and CES-D depressive symptoms ($F = 0.14, p = .71$; estimated marginal means: A β - = 5.96 [95% CI: 5.0–6.9], A β + = 5.6 [95% CI: 4.2–7.1]).

3.3 Relationships among modifiable risk factors, beta-amyloid, and cognition

Regression diagnostics were performed and indicated that all models met the necessary assumptions. Specifically, model residuals appeared normally distributed, did not exhibit heteroscedasticity, and Pearson goodness-of-fit tests were non-significant. Random effects (e.g., intercept and slope) were not correlated with residuals and the random effect residuals were normally distributed.

3.3.1 Hypertension—Likelihood ratio tests comparing full and nested linear mixed-effects models indicated that the three-way interaction of hypertension status x A β status x visit age accounted for a statistically significant amount of variance in Verbal Learning & Memory performance ($\chi^2(1) = 3.85, p = .04$; see Table 3). This result indicates that the relationship between A β and age-related decline in verbal learning and memory was a function of hypertension status (see Figure 2 [Left]). Rates of cognitive change for each group were calculated from model coefficients (Table 5) and demonstrate greater rates of decline in the elevated A β group with hypertension compared to other groups. Statistical comparison of the model coefficients using Wald test indicated that those with elevated A β and hypertension exhibited significantly greater decline than those with elevated A β without hypertension ($\beta = -0.05$ (SE=.02), $p = .046$) and those with low A β with hypertension ($\beta = -0.06$ (SE=.03), $p = .02$). The interaction of hypertension status x A β status x visit age did not account for a significant amount of variability in Speed & Flexibility performance ($\chi^2(1) = .04, p = .83$; see Table 4).

Post-hoc analyses were conducted to examine the effect of antihypertensive medication use on these results. Twenty-two percent ($n=45$) were treated with an antihypertensive

medication. Of the sample of $n=207$, $n=132$ were normotensive/non-treated, $n=35$ were normotensive/treated (e.g., blood pressure in normal range and taking an antihypertensive medication), $n=30$ were hypertensive/non-treated, and $n=10$ were hypertensive/treated (e.g., elevated blood pressure despite antihypertensive medication use). The overall three-way interaction among blood pressure status/treatment status (4-level variable) x A β status x visit age did not account for a statistically significant amount of variance in Verbal Learning & Memory performance ($\chi^2(3) = 5.82, p = .12$; see Supplemental Table 1).

3.3.2 Obesity—Likelihood ratio tests comparing the full and nested linear mixed-effects models indicated that the three-way interaction of obesity status x A β status x visit age was statistically significant for the Verbal Learning & Memory factor ($\chi^2(1) = 6.12, p = .01$; Table 3), indicating that the relationship between A β status and rate of age-related decline in verbal learning and memory was dependent on obesity status (see Figure 2 [Middle]). Rates of change in Table 5 show greater decline in those with elevated A β and obesity. Statistical comparison of model coefficients indicated that obese participants with elevated A β exhibited greater decline than non-obese participants with elevated A β ($\beta = -0.04$ (SE=.02), $p = .02$) and obese participants with low A β ($\beta = -0.05$ (SE=.02), $p = .006$). Similar to analyses with hypertension, the three-way interaction of obesity status x A β status x visit age was not associated with performance on the Speed & Flexibility factor ($\chi^2(1) = .004, p = .95$; Table 4).

3.3.3 Depression—Likelihood ratio tests comparing the full and nested linear mixed-effects models indicated that the three-way interaction of depression status x A β status x visit age was not significantly associated with Verbal Learning & Memory ($\chi^2(1) = 2.01, p = .16$; see Table 3) or Speed & Flexibility ($\chi^2(1) = 0.07, p = .80$; see Table 4) performances (see Figure 2 [right]).

3.3.4 Post-hoc sensitivity analysis—Due to lack of three-way interaction effects for any of the risk factors on the Speed & Flexibility outcome, post-hoc analyses were conducted to test if the risk factors were associated with Speed & Flexibility performance in the absence of an interaction with A β . To test this hypothesis, the three-way interaction term (risk factor status x A β status x visit age) was removed from each model and the effect of each two-way interaction (risk factor x age, A β status x age, risk factor status x A β) was examined – results indicated that the two-way interaction effects were not significantly related to Speed & Flexibility performance. To further test this hypothesis, the A β terms were removed from the models and the effect of the two-way interactions (risk factor x age) and main effects of the risk factors were examined. These results indicated non-significant interactions and main effects for hypertension and obesity factors, but a near-significant interaction effect of depression x age ($p = .08$) and a significant main effect of depression ($p = .04$) on Speed & Flexibility performance.

4. DISCUSSION

In a sample of 207 late middle-aged adults enriched for Alzheimer's disease risk, presence of hypertension or obesity moderated the relationship between A β (on PET scan or in CSF) and longitudinal verbal memory, but not speed & flexibility, performance. These findings

suggest that the presence of hypertension or obesity in midlife may exacerbate subtle cognitive decline associated with A β deposition. These results have potentially important implications for asymptomatic adults with elevated A β , which included 30% of the current sample, similar to prior reports of prevalence of elevated A β in cognitively unimpaired adults [57, 58]. The results suggest that the increased risk for cognitive decline in those with elevated A β [13, 14, 59] may be driven by those with both elevated A β and vascular risk factors. Specifically, in this sample, the annual estimated rate of memory decline was doubled in those with elevated A β and hypertension or obesity compared to those with elevated A β without hypertension or obesity. Based on this estimate, adults in the high-risk groups (A β + and hypertensive or obese) would be expected to exhibit a one standard deviation decline on the memory composite within 10 years, thus potentially crossing the threshold into the clinically impaired range earlier than those in other groups. Although the estimated rate of change is subtle, the potential to identify and modify this expected trajectory by addressing and effectively treating modifiable risk factors of hypertension and obesity could possibly result in delaying the onset of clinically significant cognitive impairment.

In contrast, the interaction among age x A β x depression was non-significant. A smaller proportion of the sample endorsed clinically significant depressive symptoms (6%) compared to those who met criteria for hypertension or obesity; it is possible that participants with depression in the larger WRAP cohort are less likely to participate in biomarker study procedures and therefore these results may reflect a biased sample of depressed individuals. Additionally, the small sample size may have reduced the power to detect a modifying effect. Further studies in larger sample sizes, as well as additional examination of types of depressive symptoms endorsed (e.g., somatic, emotional, cognitive) and the onset period of symptoms (e.g., chronically depressed vs new onset depression in mid or late life) are needed to further evaluate this relationship.

Effects of antihypertensive medication use on cognitive decline were not observed in this sample; however, it is possible that the small sizes of each cell in these post-hoc analyses may have limited statistical power to detect potential relationships. Examinations of model coefficients suggest that the hypertensive/untreated group exhibited greater rates of cognitive decline compared to the normotensive/treated group. This result should be interpreted with significant caution since the overall interaction term was non-significant; however, follow-up of this finding is warranted in a larger sample to confirm that there is no effect of antihypertensive medication use on cognitive decline in individuals with elevated levels of A β . Additionally, if treatment of midlife hypertension in those with elevated A β is associated with slowed rates of decline, clinical trials are needed to test hypotheses generated from the results of this study. Ultimately, a multi-modal intervention (i.e., similar to the FINGER study; [60]) that targets appropriate management of vascular risk factors along with physical, cognitive, and social activities may prove most effective in reducing risk for cognitive decline.

The exact cause of accelerated decline in adults with amyloid and hypertension or obesity is unknown and will require further investigation. One hypothesis is that hypertension and obesity lead to reduced cerebral blood flow and blood-brain barrier dysfunction which may

reduce A β clearance, increase A β production, and result in neuronal dysfunction and ultimately cognitive decline [61]. However, in this sample there were no differences in the proportion of participants with elevated A β by hypertension, obesity, or depression status. These findings differ from some prior reports suggesting that vascular risk factors are associated with elevated A β [36–40]. These differences may be due to the use of different analytic methods (e.g., prior studies have found that higher blood pressure is associated with greater regional A β burden [37]), the timing of the assessments (e.g., a prior study found that multiple vascular risk factors in midlife was associated with greater A β accumulation in later life [40]), or sample age (e.g., mean age of ~60 in our study compared to mean ages of 69.4 [38] and 86.9 [36]). Another hypothesis is that hypertension or obesity is associated with cerebrovascular disease and that the additive effect of A β burden and cerebrovascular disease results in accelerated decline. Our future investigations will build on the current study by incorporating markers of cerebrovascular function (e.g., white matter lesion, cerebral blood flow) and neurodegeneration (e.g., atrophy) to further investigate the potential underlying mechanisms of the decline observed in this sample.

There are several limitations of the current study that require consideration. The A β data were not collected at the same study visit for all participants which makes interpretation of the time course of biomarker positivity and vascular risk factor development on cognitive decline challenging; however, as A β is thought to accumulate gradually over the course of many years this is less likely to threaten the validity of these results. The use of dichotomous rather than continuous variables for each vascular risk factor may reduce power to detect significant effects; however, use of clinically-defined cut-points may have stronger ecological validity. Significant associations were only observed on Verbal Learning & Memory and not Speed & Flexibility performances, with the exception of a main effect of depression; exploration of individual measures that comprise this construct and evaluation across participants at varying ages may be helpful to generate additional hypotheses to test in future investigations. The sample size was relatively small for testing three-way interactions with several covariates and although the mean age was 61 there was a wide age gap across the sample (ages 40–70). Model diagnostics suggested that model assumptions were not violated and there were no influential data points; however, an initiative to increase biomarker participation in the WRAP cohort is ongoing and we plan to replicate and extend these models as more data become available. Future studies are also needed to determine whether longitudinal changes in vascular risk factors (e.g., changes in blood pressure or waist circumference) modify the effect of A β on cognitive decline and whether comorbid conditions (e.g., hypertension and obesity) or other potential modifiable factors (e.g., physical activity) are associated with longitudinal cognitive trajectories. Lastly, these studies were conducted on a sample at higher risk for AD than the general public and may not generalize to non-risk populations.

Despite these limitations, the current study adds to the literature by demonstrating that hypertension and obesity moderate relationships between A β and memory decline in late middle-age. This study supports the hypothesis that modifiable risk factors and A β interact to affect cognition, suggesting that vascular interventions in late middle-age in persons with elevated A β aggregation may mitigate effects of A β on cognition. Future work determining

if treating hypertension or obesity in late middle-age slows the rate of cognitive decline or delays the onset of clinical symptoms of dementia is needed.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

We gratefully acknowledge the assistance of researchers and staff at the Wisconsin Registry for Alzheimer's Prevention and Wisconsin Alzheimer's Disease Research Center for assistance in recruitment and data collection. We gratefully acknowledge Kaj Blennow, MD, PhD and Henrik Zetterberg, MD, PhD for assistance with cerebrospinal fluid sample assays. Most importantly, we thank the dedicated Wisconsin Registry for Alzheimer's Prevention participants for their continued support and participation in this research. This project was supported by the Clinical Translational Science Award program through the National Institutes of Health (NIH) National Center for Advancing Translational Sciences and grant UL1TR00427. This study was supported in part by a core grant to the Waisman Center from the National Institute of Child Health and Human Development (P30 HD03352). Additional funding support was provided by NIH grants R01 AG021155 (SCJ), R01 AG027161 (SCJ), ADRC P50 AG033514 (SA), R01AG037639 (BBB), R01 AG054059, F30 AG054115 (SEB), T32 GM007507 (SEB), T32 GM008692 (SEB), and T32 CA009206 (TJB).

6. REFERENCES

- [1]. Klafki H-W, Staufenbiel M, Kornhuber J, Wiltfang J. Therapeutic approaches to Alzheimer's disease. *Brain* 2006;129:2840–55. [PubMed: 17018549]
- [2]. Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. *British journal of clinical pharmacology* 2012;73:504–17. [PubMed: 22035455]
- [3]. Ikonovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. *Brain* 2008;131:1630–45. [PubMed: 18339640]
- [4]. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A β 42 in humans. *Annals of neurology* 2006;59:512–9. [PubMed: 16372280]
- [5]. Strozzyk D, Blennow K, White L, Launer L. CSF A β 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. *Neurology* 2003;60:652–6. [PubMed: 12601108]
- [6]. Chen X, Li M, Wang S, Zhu H, Xiong Y, Liu X. Pittsburgh compound B retention and progression of cognitive status—a meta-analysis. *European journal of neurology* 2014;21:1060–7. [PubMed: 24612390]
- [7]. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. *Archives of neurology* 2009;66:1469–75. [PubMed: 20008650]
- [8]. Roe C, Fagan A, Williams M, Ghoshal N, Aeschleman M, Grant E, et al. Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease. *Neurology* 2011;76:501–10. [PubMed: 21228296]
- [9]. Soldan A, Pettigrew C, Li S, Wang M-C, Moghekar A, Selnes OA, et al. Relationship of cognitive reserve and cerebrospinal fluid biomarkers to the emergence of clinical symptoms in preclinical Alzheimer's disease. *Neurobiology of aging* 2013;34:2827–34. [PubMed: 23916061]
- [10]. Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K. Cerebrospinal fluid β -amyloid 1–42 concentration may predict cognitive decline in older women. *Journal of Neurology, Neurosurgery & Psychiatry* 2007;78:461–4.
- [11]. Petersen RC, Wiste HJ, Weigand SD, Rocca WA, Roberts RO, Mielke MM, et al. Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. *JAMA neurology* 2016;73:85–92. [PubMed: 26595683]

- [12]. Ossenkoppele R, van der Flier WM, Verfaillie SC, Vrenken H, Versteeg A, van Schijndel RA, et al. Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. *Neurology* 2014;82:1768–75. [PubMed: 24748672]
- [13]. Clark LR, Racine AM, Kosciak RL, Okonkwo OC, Engelman CD, Carlsson CM, et al. Beta-amyloid and cognitive decline in late middle age: Findings from the Wisconsin Registry for Alzheimer's Prevention study. *Alzheimer's & Dementia* 2016;12:805–14.
- [14]. Lim YY, Maruff P, Pietrzak RH, Ames D, Ellis KA, Harrington K, et al. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. *Brain* 2014;137:221–31. [PubMed: 24176981]
- [15]. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. *Annals of neurology* 2010;67:122–31. [PubMed: 20186853]
- [16]. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. *The Lancet Neurology* 2011;10:819–28. [PubMed: 21775213]
- [17]. Berger A-K, Fratiglioni L, Forsell Y, Winblad B, Bäckman L. The occurrence of depressive symptoms in the preclinical phase of AD A population-based study. *Neurology* 1999;53:1998-. [PubMed: 10599771]
- [18]. Geda YE, Roberts RO, Mielke MM, Knopman DS, Christianson TJ, Pankratz VS, et al. Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: a population-based study. *American Journal of Psychiatry* 2014;171:572–81. [PubMed: 24700290]
- [19]. Green RC, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick D, et al. Depression as a risk factor for Alzheimer disease: the MIRAGE Study. *Archives of neurology* 2003;60:753–9. [PubMed: 12756140]
- [20]. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. *Archives of general psychiatry* 2006;63:530–8. [PubMed: 16651510]
- [21]. Royall DR, Palmer RF. Alzheimer's disease pathology does not mediate the association between depressive symptoms and subsequent cognitive decline. *Alzheimer's & Dementia* 2013;9:318–25.
- [22]. Sachs-Ericsson N, Joiner T, Plant EA, Blazer DG. The influence of depression on cognitive decline in community-dwelling elderly persons. *The American journal of geriatric psychiatry* 2005;13:402–8. [PubMed: 15879589]
- [23]. Verdelho A, Madureira S, Moleiro C, Ferro JM, T O'Brien J, Poggesi A, et al. Depressive symptoms predict cognitive decline and dementia in older people independently of cerebral white matter changes: the LADIS study. *J Neurol Neurosurg Psychiatry* 2013;84:1250–4. [PubMed: 23715914]
- [24]. Xu W, Tan L, Wang H-F, Jiang T, Tan M-S, Tan L, et al. Meta-analysis of modifiable risk factors for Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 2015;jnnp-2015-310548.
- [25]. Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kåreholt I, Winblad B, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. *Archives of neurology* 2005;62:1556–60. [PubMed: 16216938]
- [26]. Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. *Biological psychiatry* 2010;67:505–12. [PubMed: 19358976]
- [27]. Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP, Yaffe K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. *Bmj* 2005;330:1360. [PubMed: 15863436]
- [28]. Wolf PA, Beiser A, Elias MF, Au R, Vasan RS, Seshadri S. Relation of obesity to cognitive function: importance of central obesity and synergistic influence of concomitant hypertension. *The Framingham Heart Study. Current Alzheimer Research* 2007;4:111–6. [PubMed: 17430232]
- [29]. Sabia S, Kivimaki M, Shipley MJ, Marmot MG, Singh-Manoux A. Body mass index over the adult life course and cognition in late midlife: the Whitehall II Cohort Study. *The American journal of clinical nutrition* 2009;89:601–7. [PubMed: 19073790]

- [30]. Dahl AK, Hassing LB, Fransson EI, Gatz M, Reynolds CA, Pedersen NL. Body mass index across midlife and cognitive change in late life. *International journal of obesity* 2013;37:296–302. [PubMed: 22450854]
- [31]. Gao S, Jin Y, Unverzagt FW, Liang C, Hall KS, Ma F, et al. Hypertension and cognitive decline in rural elderly Chinese. *Journal of the American Geriatrics Society* 2009;57:1051–7. [PubMed: 19507297]
- [32]. Gottesman RF, Schneider AL, Albert M, Alonso A, Bandeen-Roche K, Coker L, et al. Midlife hypertension and 20-year cognitive change: the atherosclerosis risk in communities neurocognitive study. *JAMA neurology* 2014;71:1218–27. [PubMed: 25090106]
- [33]. Haring B, Wu C, Coker LH, Seth A, Snetselaar L, Manson JE, et al. Hypertension, dietary sodium, and cognitive decline: results from the women’s health initiative memory study. *American journal of hypertension* 2015;29:202–16. [PubMed: 26137952]
- [34]. Walker KA, Power MC, Gottesman RF. Defining the relationship between hypertension, cognitive decline, and dementia: a review. *Current hypertension reports* 2017;19:24. [PubMed: 28299725]
- [35]. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. *Neurology* 2005;64:277–81. [PubMed: 15668425]
- [36]. Harrington KD, Lim YY, Gould E, Maruff P. Amyloid-beta and depression in healthy older adults: A systematic review. *Australian & New Zealand Journal of Psychiatry* 2015;49:36–46. [PubMed: 25414381]
- [36]. Hughes TM, Kuller LH, Barinas-Mitchell EJ, McDade EM, Klunk WE, Cohen AD, et al. Arterial stiffness and β -amyloid progression in nondemented elderly adults. *JAMA neurology* 2014;71:562–8. [PubMed: 24687165]
- [37]. Langbaum JB, Chen K, Launer LJ, Fleisher AS, Lee W, Liu X, et al. Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons. *Neurobiology of aging* 2012;33:827 e11-. e19.
- [38]. Nation DA, Edland SD, Bondi MW, Salmon DP, Delano-Wood L, Peskind ER, et al. Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults. *Neurology* 2013;81:2024–7. [PubMed: 24225352]
- [39]. Chuang Y, An Y, Bilgel M, Wong D, Troncoso J, O’Brien R, et al. Midlife adiposity predicts earlier onset of Alzheimer’s dementia, neuropathology and presymptomatic cerebral amyloid accumulation. *Molecular psychiatry* 2016;21:910–5. [PubMed: 26324099]
- [40]. Gottesman RF, Schneider AL, Zhou Y, Coresh J, Green E, Gupta N, et al. Association between midlife vascular risk factors and estimated brain amyloid deposition. *Jama* 2017;317:1443–50. [PubMed: 28399252]
- [41]. Shah NS, Vidal J-S, Masaki K, Petrovitch H, Ross GW, Tilley C, et al. Midlife Blood Pressure, Plasma β -Amyloid, and the Risk for Alzheimer Disease. *Hypertension* 2012;HYPERTENSIONAHA. 111.178962.
- [42]. Johnson SC, Kosciak RL, Jonaitis EM, Clark LR, Mueller KD, Berman SE, et al. The Wisconsin Registry for Alzheimer’s Prevention: A review of findings and current directions. *Alzheimer’s & Dementia: Diagnosis, Assessment, & Disease Monitoring* 2018;In press.
- [43]. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. *Alzheimer’s & dementia : the journal of the Alzheimer’s Association* 2011;7:263–9.
- [44]. Johnson SC, Christian BT, Okonkwo OC, Oh JM, Harding S, Xu G, et al. Amyloid burden and neural function in people at risk for Alzheimer’s Disease. *Neurobiology of Aging* 2014;35:576–84. [PubMed: 24269021]
- [45]. Racine AM, Clark LR, Berman SE, Kosciak RL, Mueller KD, Norton D, et al. Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer’s Disease. *Journal of Alzheimer’s disease : JAD* 2016;54:1395–408. [PubMed: 27589532]
- [46]. Clark LR, Berman SE, Norton D, Kosciak RL, Jonaitis E, Blennow K, et al. Age-accelerated cognitive decline in asymptomatic adults with CSF beta-amyloid. *Neurology* 2018.

- [47]. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the eighth joint national committee (jnc 8). *JAMA* 2014;311:507–20. [PubMed: 24352797]
- [48]. WHO. Waist Circumference and Waist-Hip Ratio: Report of a WHO Expert Consultation. 2011.
- [49]. Lewinsohn PM, Seeley JR, Roberts RE, Allen NB. Center for Epidemiologic Studies Depression Scale (CES-D) as a screening instrument for depression among community-residing older adults. *Psychology and aging* 1997;12:277–87. [PubMed: 9189988]
- [50]. Dowling NM, Hermann B, La Rue A, Sager MA. Latent Structure and Factorial Invariance of a Neuropsychological Test Battery for the Study of Preclinical Alzheimer's Disease. *Neuropsychology* 2010;24:742–56. [PubMed: 21038965]
- [51]. Kosciak RL, La Rue A, Jonaitis EM, Okonkwo OC, Johnson SC, Bendlin BB, et al. Emergence of mild cognitive impairment in late middle-aged adults in the wisconsin registry for Alzheimer's prevention. *Dementia and geriatric cognitive disorders* 2014;38:16–30. [PubMed: 24556849]
- [52]. Hedden T, Oh H, Younger AP, Patel TA. Meta-analysis of amyloid-cognition relations in cognitively normal older adults. *Neurology* 2013;80:1341–8. [PubMed: 23547267]
- [53]. Backman L, Jones S, Berger AK, Laukka EJ, Small BJ. Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis. *Neuropsychology* 2005;19:520–31. [PubMed: 16060827]
- [54]. Duke Han S, Nguyen CP, Stricker NH, Nation DA. Detectable Neuropsychological Differences in Early Preclinical Alzheimer's Disease: A Meta-Analysis. *Neuropsychology review* 2017.
- [55]. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. 2015. 2015;67:48.
- [56]. Gibbons RD, Hedeker D, DuToit S. Advances in Analysis of Longitudinal Data. Annual review of clinical psychology 2010;6:79–107.
- [57]. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. *Neurobiology of Aging* 2010; 31:1275–1283. [PubMed: 20472326]
- [58]. Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis. *JAMA* 2015;313:1924–1938. [PubMed: 25988462]
- [59]. Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner MW, Aisen PS. Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. *Jama* 2017;317:2305–16. [PubMed: 28609533]
- [60]. Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. *The Lancet* 2015;385: 2255–2263.
- [61]. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. *Nature reviews Neuroscience* 2011;12:723–38. [PubMed: 22048062]

Research in Context

Systematic Review:

A literature review was conducted using PubMed and Web of Science databases. While relationships among beta-amyloid and modifiable risk factors including hypertension, obesity, and depression have been observed, the interaction among beta-amyloid and modifiable risk factors on longitudinal cognitive performance in midlife was not well-characterized.

Interpretation:

In a sample of 207 late middle-aged adults enriched for Alzheimer's disease risk, presence of hypertension or obesity moderated the relationship between A β (on PET scan or in CSF) and longitudinal verbal memory, but not speed & flexibility, performance. These findings suggest that hypertension or obesity in midlife may exacerbate subtle cognitive decline associated with A β deposition.

Future Directions:

Future studies are needed to determine if treatment of hypertension or obesity during midlife reduces the rate of cognitive decline and delays the onset of clinical symptoms of dementia. Further examination of physical activity level, diet, and antihypertensive medication use would be beneficial.




Figure 1.

Flow diagram of study visits. Neuropsychological evaluations are conducted at each visit. Beta-amyloid data was acquired as part of linked studies near visits 2, 3, or 4. Modifiable risk factor data were examined at the study visit closest to the biomarker acquisition visit.




Figure 2.

Graphs depict Verbal Learning & Memory z-scores on the y-axis, age at each visit (centered on mean age) on the x-axis, and estimated slopes for four beta-amyloid(A β)/risk factor groups adjusted for covariates of age at biomarker visit, sex, education, and practice effects. Risk factor groups are determined based on status at study visit closest to biomarker assessment. The left figure depicts the estimated slope for non-elevated A β and non-hypertensive (black; $n=118$), non-elevated A β and hypertensive (orange; $n=27$), elevated A β and non-hypertensive (blue; $n=49$), and elevated A β and hypertensive (green; $n=13$). The middle figure depicts the estimated slope for non-elevated A β and non-obese (black; $n=78$), non-elevated A β and obese (orange; $n=67$), elevated A β and non-obese (blue; $n=40$), and elevated A β and obese (green; $n=22$). The right figure depicts the estimated slope for non-elevated A β and non-depressed (black; $n=136$), non-elevated A β and depressed (orange; $n=9$), elevated A β and non-depressed (blue; $n=58$), and elevated A β and depressed (green; $n=4$).

Table 1.

Sample characteristics (mean (SD) or N (%))

Characteristics	Total Sample	A β +	A β -
Total Participants	207	62	145
Baseline age	54.6 (6.3)	56.7 (5.4)	53.7 (6.5)
Biomarker (PET or CSF) age	60.7 (6.4)	63.0 (5.0)	59.8 (6.7)
Biomarker visit to WRAP visit interval (yrs)	0.6 (0.5)	0.6 (0.5)	0.7 (0.5)
Sex (Female)	140 (68%)	43 (69%)	97 (67%)
Education (years)	16.1 (2.4)	16.5 (2.4)	15.9 (2.3)
<i>APOE</i> (e4 carrier)	78 (38%)	35 (57%)	43 (30%)
Parental history of AD (positive)	151 (73%)	48 (77%)	103 (71%)
Baseline Verbal Learning & Memory (z-score)	.08 (1.0)	0.17 (0.9)	0.04 (1.0)
Baseline Speed & Flexibility (z-score)	-0.003 (0.9)	-0.19 (0.9)	0.07 (1.0)
Beta-amyloid modality	CSF: 26 (13%) PiB: 75 (36%) Both: 106 (51%) ^a	CSF: 5 (8%) PiB: 19 (31%) Both: 38 (61%)	CSF: 21 (15%) PiB: 56 (39%) Both: 68 (47%)
Hypertension ^b	40 (19%)	13 (21%)	27 (19%)
Obesity ^c	89 (43%)	22 (36%)	67 (46%)
Depression ^d	13 (6%)	4 (7%)	9 (6%)
Diabetes	4 (2%)	0 (0%)	4 (3%)
Tobacco use (current smoker)	8 (4%)	2 (3%)	6 (4%)
Systolic blood pressure	125.8 (15.7)	126.2 (16.1)	125.6 (15.6)
Diastolic blood pressure	74.4 (9.7)	74.7 (9.9)	74.4 (9.6)
Waist circumference (cm)	92.3 (14.9)	90.3 (15.1)	93.2 (14.8)
Center for Epidemiologic Studies of Depression scale	5.9 (5.9)	5.6 (5.1)	6.0 (6.2)
Anti-hypertensive medication use	45 (22%)	18 (29%)	27 (19%)

^aOf these 106, $n=85$ (80%) were congruent across modalities and $n=21$ (20%) were incongruent ($n=9$ were classified as beta-amyloid positive by PiB, but negative by CSF and $n=12$ were classified as beta-amyloid positive by CSF, but negative by PiB). Positivity status using either modality resulted in classification in the beta-amyloid positive group.

^b(systolic blood pressure > 139 or diastolic blood pressure > 89)

^c(waist circumference > 102 cm for males or > 88 cm for females)

^d(Center for Epidemiologic Studies of Depression scale - 16)

Table 2.Beta-amyloid (A β) status by risk factor status (*n* (%))

A β status	Hypertension		Obesity		Depression		Total
	<i>Normal</i>	<i>Elevated^a</i>	<i>Normal</i>	<i>Elevated^b</i>	<i>Normal</i>	<i>Elevated^c</i>	
Non-elevated	118 (81)	27 (19)	78 (54)	67 (46)	136 (94)	9 (6)	145
Elevated	49 (79)	13 (21)	40 (65)	22 (35)	58 (94)	4 (6)	62
Total	167 (81)	40 (19)	118 (57)	89 (43)	194 (94)	13 (6)	207
$\chi^2(1), p$.15	.70	2.04	.15	.004	.95	

^a(systolic blood pressure > 139 or diastolic blood pressure > 89)

^b(waist circumference > 102 cm for males or > 88 cm for females)

^c(Center for Epidemiologic Studies of Depression scale = 16)

Note: *n*=20 participants are in both elevated hypertension and elevated obesity groups, *n*=8 participants are in both elevated obesity and elevated depression groups, *n*=2 participants are in both elevated hypertension and elevated depression groups, *n*=1 participant was elevated on all 3 risk factors.

Table 3.

Model parameter estimates for association between presence of modifiable risk factors and Verbal Learning & Memory outcome

	Risk Factor		
	Hypertension	Obesity	Depression
	β (SE); [95% CI]	β (SE); [95% CI]	β (SE); CI
Intercept	-2.3 (1.6); [-5.3, 0.7]	-2.2 (1.6); [-5.2, 0.9]	-2.3 (1.6); [-5.4, 0.7]
Risk factor group	-0.2 (0.2); [-0.5, 0.1]	-0.1 (0.1); [-0.4, 0.1]	-0.1 (0.3); [-0.7, 0.4]
Beta-amyloid (A β) group	0.04 (0.1); [-0.2, 0.3]	-0.001 (0.2); [-0.3, 0.3]	0.2 (0.1); [-0.1, 0.4]
Centered visit age (slope)	-0.04 (0.02); [-0.1, 0.01]	-0.04 (0.02); [-0.1, 0.002]	-0.04 (0.02); [-0.1, 0.01]
Biomarker age	0.01 (0.02); [-0.04, 0.1]	0.01 (0.02); [-0.04, 0.1]	0.01 (0.02); [-0.04, 0.1]
Sex	0.8 ^{***} (0.1); [0.6, 1.1]	0.8 ^{***} (0.1); [0.6, 1.1]	0.8 ^{***} (0.1); [0.6, 1.1]
Education	0.1 ^{**} (0.02); [0.03, 0.1]	0.1 ^{**} (0.02); [0.02, 0.1]	0.1 ^{**} (0.02); [0.02, 0.1]
Practice effect	0.1 (0.1); [-0.03, 0.2]	0.1 (0.1); [-0.02, 0.2]	0.1 (0.1); [-0.02, 0.2]
Treatment status	0.1 (0.1); [-0.2, 0.3]	--	-0.1 (0.1); [-0.3, 0.1]
Risk factor group x A β group	0.4 (0.3); [-0.2, 1.0]	0.3 (0.2); [-0.1, 0.8]	-0.7 (0.5); [-1.6, 0.3]
Centered visit age x Risk factor group	0.01 (0.01); [-0.02, 0.03]	0.01 (0.01); [-0.01, 0.03]	-0.03 (0.02); [-0.1, 0.02]
Centered visit age x A β group	-0.01 (0.01); [-0.03, 0.02]	0.01 (0.01); [-0.02, 0.03]	-0.02 (0.01); [-0.04, 0.004]
Centered visit age x A β group x Risk factor group	-0.1 [*] (0.03); [-0.1, -0.001]	-0.1 (0.02) ^{**} ; [-0.1, -0.01]	0.1 (0.04); [-0.02, 0.1]

^{***}
p .001

^{**}
p .01

^{*}
p .05

p-values for fixed effect coefficients were calculated using asymptotic properties of the estimates

Table 4.

Model parameter estimates for association between presence of modifiable risk factors and Speed & Flexibility outcome

	Risk Factor		
	Hypertension	Obesity	Depression
	β (SE); [95% CI]	β (SE); [95% CI]	β (SE); [95% CI]
Intercept	4.3 ** (1.4); [1.6, 7.0]	4.3 ** (1.4); [1.6, 7.0]	4.1 ** (1.4); [1.4, 6.8]
Risk factor group	0.1 (0.2); [-0.2, 0.4]	0.1 (0.1); [-0.1, 0.4]	-0.4 (0.3); [-0.8, 0.1]
Beta-amyloid (A β) group	-0.1 (0.1); [-0.3, 0.2]	0.02 (0.1); [-0.3, 0.3]	-0.1 (0.1); [-0.3, 0.2]
Age at each visit (centered)	0.002 (0.02); [-0.04, 0.04]	0.01 (0.02); [-0.03, 0.04]	-0.0001 (0.02); [-0.04, 0.04]
Biomarker age	-0.1 *** (0.02); [-0.1, -0.03]	-0.1 *** (0.02); [-0.1, -0.03]	-0.1 *** (0.02); [-0.1, -0.03]
Sex	-0.02 (0.1); [-0.2, 0.2]	-0.04 (0.1); [-0.3, 0.2]	-0.01 (0.1); [-0.2, 0.2]
Education	-0.002 (0.02); [-0.04, 0.04]	-0.001 (0.02); [-0.04, 0.04]	0.001 (0.02); [-0.04, 0.04]
Practice effect	0.05 (0.1); [-0.1, 0.2]	0.04 (0.1); [-0.1, 0.1]	0.1 (0.1); [-0.1, 0.2]
Medication use	0.005 (0.1); [-0.2, 0.3]	--	-0.03 (0.1); [-0.2, 0.2]
Risk factor group x A β group	0.04 (0.3); [-0.5, 0.6]	-0.2 (0.2); [-0.7, 0.2]	-0.2 (0.4); [-1.1, 0.7]
Centered visit age x Risk factor group	-0.003 (0.01); [-0.03, 0.02]	-0.005 (0.01); [-0.02, 0.01]	-0.03 (0.02); [-0.1, 0.01]
Centered visit age x A β group	-0.01 (0.01); [-0.03, 0.01]	-0.02 (0.01); [-0.04, 0.01]	-0.01 (0.01); [-0.03, 0.004]
Centered visit age x A β group x Risk factor group	-0.01 (0.02); [-0.1, 0.04]	0.001 (0.02); [-0.04, 0.04]	0.01 (0.03); [-0.1, 0.1]

p .001

**
p .01

*
p .05

p-values for fixed effect coefficients were calculated using asymptotic properties of the estimates

Table 5.

Estimated annual rates of cognitive change (z-score units) across groups

	Verbal Learning & Memory	Speed & Flexibility
Hypertension	β [95% CI]	β [95% CI]
A β -/HTN-	-0.039 [-0.083, 0.005]	0.002 [-0.037, 0.041]
A β +/HTN-	-0.043 [-0.089, 0.002]	-0.011 [-0.051, 0.029]
A β -/HTN+	-0.033 [-0.083, 0.017]	-0.001 [-0.044, 0.042]
A β +/HTN+	-0.091 [-0.150, -0.032]	-0.020 [-0.073, 0.032]
Obesity		
A β -/OB-	-0.043 [-0.089, 0.002]	0.005 [-0.035, 0.045]
A β +/OB-	-0.038 [-0.084, 0.009]	-0.010 [-0.051, 0.030]
A β -/OB+	-0.032 [-0.077, 0.013]	0.001 [-0.039, 0.040]
A β +/OB+	-0.082 [-0.134, -0.030]	-0.014 [-0.059, 0.031]
Depression		
A β -/DEP-	-0.038 [-0.082, 0.007]	-0.0001 [-0.039, 0.038]
A β +/DEP-	-0.056 [-0.102, -0.011]	-0.014 [-0.053, 0.026]
A β -/DEP+	-0.067 [-0.127, -0.006]	-0.030 [-0.085, 0.025]
A β +/DEP+	-0.028 [-0.102, 0.046]	-0.035 [-0.095, 0.025]

A β =beta-amyloid; HTN=hypertension; OB=obesity; DEP=depression

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript